Citations

Clear

199 citation(s) found for "Lu, Cathy".

Fruquintinib plus best supportive care for patients with metastatic colorectal cancer: Characterization of patients who had an overall survival of ≥10 months in the FRESCO-2 study.
Randrian, Violaine , Sobrero, Alberto F. , Höchster, Howard S. , Cutsem, Eric Van, Yu, Ziji, Dong, Cynthia, Schelman, William R., Kasper, Stefan , Bianchi, Andrea Sartore , Cremolini, Chiara , Arnold, Dirk , Dasari, Arvind , Eng, Cathy , Lonardi, Sara , Élez, Elena , Yoshino, Takayuki , Yao, James C. , Cutsem, Eric Van , Tougeron, David , Dong, Cynthia, Ghiringhelli, François

Mayo Clinic

Journal of Clinical Oncology | January 27, 2025 | Volume: 43 | Issue: 4_suppl | Pages: 142-142

10.1200/jco.2025.43.4_suppl.142 Get It

142 Background: Fruquintinib (F) is a highly selective, oral tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors (VEGFRs -1, -2, -3) that is approved by the US FDA and in the EU, UK, and Japan for previously treated metastatic colorectal cancer (mCRC), regardless of biomarker status. FRESCO-2 (NCT04322539) met its primary endpoint demonstrating significantly improved overall survival (OS) with F + best supportive care (BSC) vs placebo (P) + BSC. This subgroup analysis assessed landmark survival of all FRESCO-2 patients (pts), and baseline (BL) characteristics and safety data of pts treated with F who had OS ≥10 months (mos) compared with the intent-to-treat (ITT) population (pop). Methods: Pts were randomized 2:1 to receive F 5 mg or matching P, by mouth, once daily, 3 weeks on, 1 week off, + BSC. Pts had received prior chemotherapy, anti-VEGF therapy and, if RAS wild type, anti-EGFR therapy; and had prior exposure to trifluridine/tipiracil (TAS-102) and/or regorafenib. The hazard ratio (HR) between the two treatment arms was calculated from a stratified Cox proportional hazard model with treatment group as the only covariate in the model. Results: In the ITT pop, OS was improved with F vs P (HR 0.66); OS rates (95% confidence intervals [CIs]) at 6 and 9 mos were 60.4% (55.9–64.9) vs 41.5% (35.0–48.0) and 41.1% (36.4–45.8) vs 28.2% (22.1–34.3), respectively. Progression-free survival (PFS) rates (95% CIs) at 6 and 9 mos were 23.8% (19.7–28.0) vs 1.1% (0–2.6) and 11.3% (8.1–14.6) vs 0.5% (0–1.6), respectively. Of 461 pts who received F, 113 (24.5%) had OS ≥10 mos (range 10.0–18.9) with a median duration of F treatment of 6.3 mos (range 0.7–19.1). Among pts receiving F, a higher proportion (≥10% difference) of pts with OS ≥10 mos had no liver metastases (mets) and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 at BL compared with the ITT pop (Table). In pts with OS ≥10 mos, 61.9% experienced a grade ≥3 treatment-emergent adverse event compared with 62.7% in the ITT pop. Conclusions: Longer-term OS and PFS rates at 6 and 9 mos were higher with F vs P in the FRESCO-2 ITT pop. The data show a higher proportion of pts with OS ≥10 mos had an absence of liver mets and ECOG PS 0 at BL than the ITT pop. The safety profile of F in pts with OS ≥10 mos was consistent with the ITT pop. Clinical trial information: NCT04322539 . BL characteristics of pts treated with F with OS ≥10 mos vs ITT pop. BL characteristic Pts with OS ≥10 mos (n=113) ITT pop(n=461) ECOG PS (0 / 1), % 54.0 / 46.0 42.5 / 57.5 Median time since 1 st CRC diagnosis, mos 52.0 47.2 Primary tumor location at 1 st diagnosis (colon / rectum / both), % 51.3 / 35.4 / 13.3 60.5 / 31.0 / 8.5 Primary site at 1 st diagnosis (colon left / colon right), % 42.5 / 15.9 41.6 / 21.0 Liver mets, % 58.4 73.5 Median duration of mCRC, mos 42.7 37.9 Prior lines of therapy for mCRC (≤3 / >3), % 26.5 / 73.5 27.1 / 72.9 Prior TAS-102, % 46.9 52.1 Prior regorafenib, % 12.4 8.7
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline
Morris, Van K. , Kennedy, Erin B. , Amin, Manik , Aranha, Olivia , Benson, Al B. , Dorth, Jennifer A. , Horowitz, David P. , Kennecke, Hagen F. , Kim, Stéfano , Kreppel, Lillian, Rajdev, Lakshmi , Mettu, Niharika B , Riechelmann, Rachel , Sio, Terence T , Eng, Cathy , Riechelmann, Rachel P. , Sio, Terence T. , Eng, Cathy

Mayo Clinic

Journal of Clinical Oncology | December 16, 2024 | Volume: 43 | Issue: 5 | Pages: 605-615

10.1200/jco-24-02120 | PMID 39680825 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgement. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard-of-care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only). PURPOSE To provide evidence-based guidance for clinicians who treat patients with stage I-III anal cancer. METHODS A systematic review of the literature conducted by the Minnesota Evidence-based Practice Center provided the evidence base for this guideline. An ASCO Expert Panel reviewed this evidence and came to consensus on a set of evidence-based recommendations. RESULTS The systematic review contained three randomized controlled trials and three nonrandomized studies of interventions that were relevant to the guideline topic and informed the recommendations. RECOMMENDATIONS Mitomycin-C (MMC) with a fluoropyrimidine (fluorouracil [FU] or capecitabine) is recommended as the radiosensitizing component of chemoradiation (CRT) for anal cancer; the Expert Panel recognizes that capecitabine is often used as an orally administered alternative to FU and is currently being used in ongoing clinical trials. Cisplatin with FU is an additional chemotherapy combination that may be recommended as radiosensitizing chemotherapy. Because of the myelosuppression associated with MMC, the preferable regimen for patients with immunosuppression is cisplatin and FU. Cisplatin is not recommended for patients with renal dysfunction, significant neuropathy, or hearing loss, and there is no evidence to recommend substituting carboplatin for cisplatin. Dose and schedule options for recommended chemotherapy agents are included within the full text of the guideline. Routine induction chemotherapy before CRT and additional chemotherapy after CRT are not recommended for patients with localized anal cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Examining Discrepancies in Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Novel Therapies across Diverse Clinical Landscapes: An International Prospective Study
Biru, Yelak, Miguel, Maite San, Cormier, Nicolas , Sato, Anna, Zeanah, Cathy, Goldman, Erinn Hoag, Popat, Rakesh , Ailawadhi, Sikander , Clavreul, Solène , Miguel, Maite San, Sato, Anna, Farrell, James, Popat, Rakesh

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3658-3658

10.1182/blood-2024-208007 Get It

Introduction: Given the major treatment advancements in relapsed/refractory multiple myeloma (RRMM) such as bispecific antibodies (BsAbs), understanding patient and healthcare provider (HCP) decision-making perspectives is crucial. This study investigated barriers to adopting resource-intensive novel therapies, unmet needs in access to care, and treatment decision priorities in one of the largest surveys of RRMM patients and HCPs. Methods: This prospective study was conducted from March to June 2024 using 30-minute web-based quantitative surveys fielded in 2269 participants (1301 RRMM patients and 968 HCPs) across 7 countries (US, UK, France, Germany, Italy, Spain, Japan). The survey collected data on pre-defined patient subgroups (line of treatment, ages <45, 46-65, 65+]) and in HCP subgroups (care settings: academic, community [non-Center of Excellence [COE]). Data were analyzed using descriptive statistics and chi-square tests. Results: Two themes that emerged from the findings were: 1) discrepancies in treatment considerations between patients and HCPs, and 2) Familiarity with and considerations around BsAbs among patients Discrepancies in HCP and Patient considerations HCPs and patients prioritized different considerations during treatment decision-making, particularly related to the importance of treatment related adverse events (TRAEs). 3L+ patients equally prioritized disease control and minimizing TRAEs (49% and 49%); HCPs prioritized disease control more often than minimizing TRAEs (59% and 40% for 3L+ patients). Patients considered many TRAEs extremely challenging to manage, whereas HCPs were less likely to do so (patients vs HCPs: bone-related AEs: 64% vs 39%, p<0.001; hypertension: 54% vs 28%, p<0.001; cholesterol: 53% vs 21%, p<0.001; skin-related AEs: 49% vs 30%, p<0.001). Limiting TRAEs was a concern particularly among patients over 65 (52%, p<0.001) and those with comorbidities (52%, p<0.001). Limiting costs and financial challenges (3L+ patients: 33% vs HCPs: 13%, p<0.001) and avoiding compromising the potential to receive treatment options in later lines (3L+ patients: 25% vs HCPs:14%, p<0.001) were other considerations patients prioritized more than HCPs. HCPs prioritized limiting side effects 9% more in 3L settings compared to 2L. Discrepancies in decision-making in 2L setting included a desire to limit treatment-related logistical burden (patients: 35% vs HCP: 17%, p<0.001), limit challenges for care partners (25% vs 13%, p<0.001), and ensure treatment without referral (24% vs 16%, p=0.001). Compared to their older counterparts, younger patients (<45 y v ≥45y) prioritized convenient treatment administration (39% vs 29%, p=0.024) and avoiding referrals to other institutions (32% vs 22%, p<0.001). Perspectives on treatment considerations specific to BsAbs Among 3L+ patients, most have not heard of BsAbs, or have heard but were unfamiliar with the option. A small proportion of 3L+ patients recalled their HCPs suggesting BsAbs as a treatment option (14%) although most patients decided to receive BsAbs treatment when it was offered (71%). Among patients on BsAb treatment, patients most often cited clinical reasons for going on BsAbs (i.e., remission, symptom relief, and likelihood of greater longevity). Among non-clinical reasons, lower time commitment and lower likelihood of negative financial impact compared with other treatments were also common. Notably, 36% of HCPs reported low confidence in identifying RRMM patients eligible for BsAbs. Compared with academic HCPs (32%), more community/non-COE HCPs (42% p=0.018) reported low confidence. Conclusions: HCPs and patients have different priorities during treatment decision-making, particularly regarding the importance of minimizing TRAE and in prioritizing efficacy and managing logistical burdens in later treatment lines. Among novel treatments, BsAbs are not frequently recalled by patients as a treatment option provided by HCPs. HCPs, especially in community settings, are often uncertain about identifying eligible patients for BsAbs, indicating a need for greater educational resources for HCPs. Increasing patient awareness of available treatments, HCP understanding of novel treatments, and fostering dialogue on patient priorities can increase the likelihood of informed, personalized shared decision-making, and optimize evidence-based patient outcomes.
35 Hardwiring psychological safety as the foundation for a successful quality and safety program
Hannafin, Cathy, Ponce, Lisa , Bowman, Andrew W. , Flug, Jonathan A.

Mayo Clinic

Oral Presentation (OP) Abstracts | December 1, 2024 | Volume: No volume available | Issue: No issue available | Pages: A24.1-A24

10.1136/bmjoq-2024-ihi.35 Get It

Prevention and Treatment of Cancer-Related Infections, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Baden, Lindsey R. , Almyroudis, Nikolaos G. , Angarone, Michael , Baluch, Aliyah , Barros, Nicolas , Buss, Brian, Cohen, Stuart H. , Cooper, Brenda , Chiang, Augusto Dulanto , Boghdadly, Zeinab El , Gregg, Kevin , Hakim, Hana , Ho, Dora Y. , Lee, Rachael , Lee, Francesca , Logan, Cathy , Manley, Kristen, Pisano, Jennifer , Saullo, Jennifer L. , Schuster, Mindy G. , Seo, Susan K. , Taplitz, Randy , Topal, Jeffrey , Wilson, John , Zimmer, Andrea , Cassara, Carly J., Diwan, Zeenat, Swaminathan, Sankar , Khawaja, Fareed , Multani, Ashrit , Pande, Anupam , Pergam, Steven A. , Shoham, Shmuel , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 13, 2024 | Volume: 22 | Issue: 9 | Pages: 617-644

10.6004/jnccn.2024.0056 | PMID 39536464 Get It

There is an increased risk of infection in patients with cancer that results in higher morbidity and mortality. Several risk factors can predispose these patients to infectious complications. Some such factors include immunocompromised states like neutropenia, allogeneic hematopoietic cell transplantation, and graft-versus-host disease, while others include immunosuppressive agents like corticosteroids, purine analogs, monoclonal antibodies, and other emerging cancer therapeutics like CAR T-cell therapy. The NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections address infection concerns that may be observed in these immunocompromised populations and characterize the major pathogens to which patients with cancer are susceptible, with a focus on the prevention, diagnosis, and treatment of major common and opportunistic infections. This paper highlights 2 recently updated sections of the guidelines, namely, infection concerns related to CAR T-cell therapy and antimicrobial prophylaxis recommendations, including vaccination, in patients at high-risk for infections.
174: Foot drop prevention in extracorporeal membrane oxygenation (ECMO) patients.
Barr, Jo’el, Mielke, Cathy, Shimp, Julie, Kiley, Sean , Birst, Jennifer, Worsowicz, Greg, Daron, Kristien L., Zimmerman, Jill, SHIMP, JULIE, Pham, Si M.

Mayo Clinic

ASAIO Journal | September 28, 2024 | Volume: 70 | Issue: Supplement 4 | Pages: 21-21

10.1097/01.mat.0001069852.42787.92 Get It

A Genotype/Phenotype Study of KDM5B-Associated Disorders Suggests a Pathogenic Effect of Dominantly Inherited Missense Variants
Borroto, Maria Carla , Michaud, Coralie , Hudon, Chloé, Agrawal, Pankaj B. , Agre, Katherine , Applegate, Carolyn , Beggs, Alan H. , Callewaert, Bert , Chen, Mei-Jan, Curry, Cynthia J. , Devinsky, Orrin , Dudding‐Byth, Tracy , Fagan, K, Finnila, Candice R. , Gavrilova, Ralitza, Hiatt, Susan M. , Hildebrandt, Friedhelm , Wojcik, Monica H. , Kleefstra, Tjitske, Kolvenbach, Caroline M. , Korf, Bruce R. , Kruszka, Paul , Li, Hong , Litwin, Jessica, Marcadier, Julien , Platzer, Konrad , Blackburn, Patrick R. , Reijnders, Margot R.F. , Reutter, Heiko , Schanze, Ina, Shieh, Joseph T.C. , Stevens, Cathy A., Valivullah, Zaheer M. , Boogaard, Marie‐José H. van den , Klee, Eric W. , Campeau, Philippe M. , Applegate, Carolyn D , Callewaert, Bert , Devinsky, Orrin , Wojcik, Monica H , Kruszka, Paul , Platzer, Konrad , Reutter, Heiko , van den Boogaard, Marie-José , Klee, Eric W , Campeau, Philippe M , Beggs, Alan H , Björnsson, Hans T. , Genetti, Casie A. , Kleefstra, Tjitske

Mayo Clinic

Genes | August 6, 2024 | Volume: 15 | Issue: 8 | Pages: 1033

10.3390/genes15081033 | PMID 39202393 Get It

Bi-allelic disruptive variants (nonsense, frameshift, and splicing variants) in KDM5B have been identified as causative for autosomal recessive intellectual developmental disorder type 65. In contrast, dominant variants, usually disruptive as well, have been more difficult to implicate in a specific phenotype, since some of them have been found in unaffected controls or relatives. Here, we describe individuals with likely pathogenic variants in KDM5B, including eight individuals with dominant missense variants. This study is a retrospective case series of 21 individuals with variants in KDM5B. We performed deep phenotyping and collected the clinical information and molecular data of these individuals’ family members. We compared the phenotypes according to variant type and to those previously described in the literature. The most common features were developmental delay, impaired intellectual development, behavioral problems, autistic behaviors, sleep disorders, facial dysmorphism, and overgrowth. DD, ASD behaviors, and sleep disorders were more common in individuals with dominant disruptive KDM5B variants, while individuals with dominant missense variants presented more frequently with renal and skin anomalies. This study extends our understanding of the KDM5B-related neurodevelopmental disorder and suggests the pathogenicity of certain dominant KDM5B missense variants.
Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2.
Sobrero, Alberto , García‐Alfonso, Pilar , Höchster, Howard S. , Qin, Shukui , Schelman, William R., Fan, Songhua, Yu, Ziji, Chen, Lucy F., Bekaii‐Saab, Tanios , Dasari, Arvind , Eng, Cathy , Lonardi, Sara , Yoshino, Takayuki , Yao, James C. , Bianchi, Andrea Sartore , Hubbard, Joleen M. , Price, Timothy Jay , Tougeron, David , Li, Jin , Tabernero, Josep

Mayo Clinic

Journal of Clinical Oncology | July 5, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 3579-3579

10.1200/jco.2024.42.16_suppl.3579 Get It

3579 Background: Fruquintinib (F) is a highly selective, oral tyrosine kinase inhibitor of all 3 VEGF receptors. Based on FRESCO (NCT02314819) and FRESCO-2 (NCT04322539) data, F was approved by the US FDA for previously treatedmetastatic colorectal cancer (mCRC). Efficacy and safety of F + best supportive care (BSC) vs placebo (P) + BSC were analyzed according to prior treatment (tx) sequence using FRESCO and FRESCO-2 data. Methods: In FRESCO and FRESCO-2, patients (pts) were randomized 2:1 to receive F 5 mg or matching P, PO daily x 21 days every 28 days. In FRESCO, eligible pts had received ≥2 prior chemotherapy regimens and were permitted to have received prior anti-VEGF and/or anti-EGFR therapies, whereas in FRESCO-2, in addition to standard chemotherapies, anti-VEGF, and anti-EGFR therapies if indicated, prior exposure to trifluridine/tipiracil (TAS) and/or regorafenib (rego) was required. FRESCO-2 pts must have also received a BRAF inhibitor and/or immunotherapy, if indicated and available in their country. Results: In FRESCO (F n=278 vs P n=138), no pts had received rego and 16/416 pts (4%) had received TAS. InFRESCO-2, prior therapies were balanced between F vs P arms; pts had received prior TAS or rego in these sequences: prior TAS only (n=240 vs n=121); prior rego only (n=40 vs n=18); prior rego then TAS (n=84 vs n=45); prior TAS then rego (n=95 vs n=44). Improvements in OS and PFS were seen with F vs P regardless of prior tx sequence (Table), with similar magnitudes of benefit for OS (HRs 0.53–0.77) and PFS (HRs 0.25–0.37). F safety profile was consistent regardless of prior tx sequence (Table). Conclusions: F is effective in mCRC with a manageable safety profile regardless of prior TAS or rego tx and sequence. Improvement with F was similar for OS and PFS despite the number and sequence of prior regimens. F provides a new tx option for pts with previously treated mCRC regardless of prior TAS or rego exposure. Clinical trial information: NCT04322539 . [Table: see text]